ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
UA mitigates cisplatin-induced toxicity suggesting involvement of the KEAP1-NRF2 pathway: insights from histopathological validation, molecular docking, and molecular dynamics.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is a widely used chemotherapeutic agent known for its potent antitumor activity, however its clinical use is significantly limited by dose-dependent multiorgan toxicity predominantly affecting the kidney, heart and reproductive organs, with mechanisms involving oxidative stress, mitochondrial dysfunction, inflammation and apoptosis. In this study the potential protective effects of ursolic acid (UA), a pentacyclic triterpenoid with known antioxidant and antiapoptotic properties, against cisplatin-induced organ toxicity was explored. Thirty Swiss albino mice were randomly divided into five groups including control, cisplatin-treated, cisplatin + low-dose UA, cisplatin + high-dose UA and UA alone, with cisplatin (10 mg/kg, i.p.) given as a single dose and UA administered daily for 14 days, and kidney, heart and testis tissues were examined histologically showing that cisplatin caused glomerular and tubular degeneration, myocardial disarray with inflammatory infiltration and degeneration of seminiferous tubules, while UA co-administration significantly reduced these histopathological alterations in a dose-dependent manner, and serum reactive oxygen species (ROS) levels confirmed its antioxidant potential, and further molecular docking followed by 200 ns molecular dynamic simulations in GROMACS targeting the KEAP1-NRF2 complex (PDB ID: 2FLU) showed strong binding of UA (-7.2 kcal/mol), comparable to curcumin supporting a possible role in NRF2 activation, and simulation analysis demonstrated that both UA-KEAP1 and curcumin-KEAP1 complexes formed stable interactions with UA exhibiting slightly lower RMSD fluctuations and consistent radius of gyration values indicating a compact and dynamically stable complex, suggesting that UA may offer protection against cisplatin-induced toxicity by modulating oxidative stress and the KEAP1-NRF2 pathway.
Indexed as
Identifiers
42012660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.